Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability

Abstract

The azoxymethane (AOM)-induced mouse colon tumor model recapitulates many of the histopathological features associated with the multistage progression of human sporadic colorectal cancers (CRCs). To better define the genetic events associated with tumorigenesis in this murine model, we analysed tumors from A/J mice for chromosomal (CIN) and microsatellite (MSI) instabilities, two fundamental pathways of genomic instability that play a critical role in the pathogenesis of human CRCs. Male A/J mice, 6-week old, were injected with either AOM (n=5) (10 mg/kg b.w., i.p.) or vehicle (n=5) (0.9% NaCl solution) once a week for 6 weeks. At 32 weeks after the last dose, comparative genomic hybridization (CGH) was performed on 16 tumors harvested from five animals. Although 25% of the tumors displayed either a gain of chromosome 2 or loss of Y, the majority (75%) showed no genomic imbalances. Further analysis of chromosomal aberrations, using CGH and spectral karyotyping (SKY) was performed in our recently established A/J colon tumor-derived cell line, AJ02-NM0. Results showed a pseudotetraploid karyotype with loss of only the Y chromosome in these cultured cells, thereby providing additional evidence for the minimal role of CIN in the primary AOM-induced tumors. Interestingly, the majority (81%) of A/J tumors displayed low-level microsatellite instability (MSI-L) when analysed using mono- and dinucleotide repeat markers, and showed a significant expansion to high-level instability (MSI-H) in the AJ02-NM0 cells. This finding in cultured cells additionally provides evidence that a mild mutator pathway may contribute to the development of behaviorally benign carcinomas in situ in A/J mice. To better understand the tumorigenic process in the A/J colons, we screened for mutational alterations in key regions of the K-ras and Apc genes. Results showed a very low frequency (6%) of K-ras activating mutations, together with the absence of Apc truncation mutations in primary tumors and AJ02-NM0 cells. However, these tumors displayed intense nuclear accumulation of β-catenin protein, indicating activation of the Wnt signaling pathway. Based on our molecular and cytogenetic findings, we propose that carcinogen-induced tumors may develop via mechanisms independent of the ‘classical’ CIN or MSI pathways.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Abbreviations

AOM:

azoxymethane

CRC:

colorectal cancer

CGH:

comparative genomic hybridization

CIN:

chromosomal instability

MSI:

microsatellite instability

MSS:

microsatellite stable

MSI-L:

low-level microsatellite instability

MSI-H:

high-level microsatellite instability

SKY:

spectral karyotyping

FAP:

familial adenomatous polyposis

HNPCC:

hereditary nonpolyposis colorectal cancer

K-ras:

Kirsten rat sarcoma oncogene

Apc:

adenomatosis polyposis coli

MCR:

mutational cluster region

MMR:

mismatch repair

References

  • Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruine AP, Goldbohm RA and van den Brandt PA . (2003). Carcinogenesis, 24, 703–710.

  • Calvert PM and Frucht H . (2002). Ann. Intern. Med., 137, 603–612.

  • Chan TL, Curtis LC, Leung SY, Farrington SM, Ho JW, Chan AS, Lam PW, Tse CW, Dunlop MG, Wyllie AH and Yuen ST . (2001). Oncogene, 20, 4871–4876.

  • Corpet DE and Pierre F . (2003). Cancer Epidemiol. Biomarkers Prev., 12, 391–400.

  • De Filippo C, Caderni G, Bazzicalupo M, Briani C, Giannini A, Fazi M and Dolara P . (1998). Br. J. Cancer, 77, 2148–2151.

  • Dong M, Guda K, Nambiar PR, Rezaie A, Belinsky GS, Lambeau G, Giardina C and Rosenberg DW . (2003). Carcinogenesis, 24, 307–315.

  • Eshleman JR, Casey G, Kochera ME, Sedwick WD, Swinler SE, Veigl ML, Willson JK, Schwartz S and Markowitz SD . (1998). Oncogene, 17, 719–725.

  • Fearnhead NS, Britton MP and Bodmer WF . (2001). Hum. Mol. Genet., 10, 721–733.

  • Fearon ER and Vogelstein B . (1990). Cell, 61, 759–767.

  • Georgiades IB, Curtis LJ, Morris RM, Bird CC and Wyllie AH . (1999). Oncogene, 18, 7933–7940.

  • Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM and Boland CR . (2003). Cancer Res., 63, 1608–1614.

  • Guda K, Giardina C, Nambiar P, Cui H and Rosenberg DW . (2001). Mol. Carcinog., 31, 204–213.

  • Haag JD, Brasic GM, Shepel LA, Newton MA, Grubbs CJ, Lubet RA, Kelloff GJ and Gould MN . (1999). Mol. Carcinog., 24, 47–56.

  • Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, Roemen G, Arends JW, Williams R, Giaretti W, De Goeij A and Meijer G . (2002). Gastroenterology, 123, 1109–1119.

  • Hoglund M, Gisselsson D, Hansen GB, Sall T, Mitelman F and Nilbert M . (2002). Cancer Res., 62, 5939–5946.

  • Iino H, Jass JR, Simms LA, Young J, Leggett B, Ajioka Y and Watanabe H . (1999). J. Clin. Pathol., 52, 5–9.

  • Jass JR . (2003). J. Pathol., 199, 267–269 author reply 269–70.

  • Jass JR, Biden KG, Cummings MC, Simms LA, Walsh M, Schoch E, Meltzer SJ, Wright C, Searle J, Young J and Leggett BA . (1999). J. Clin. Pathol., 52, 455–460.

  • Jass JR, Walsh MD, Barker M, Simms LA, Young J and Leggett BA . (2002). Eur. J. Cancer, 38, 858–866.

  • Kambara T, Matsubara N, Nakagawa H, Notohara K, Nagasaka T, Yoshino T, Isozaki H, Sharp GB, Shimizu K, Jass J and Tanaka N . (2001). Cancer Res., 61, 7743–7746.

  • Kislitsin D, Lerner A, Rennert G and Lev Z . (2002). Dig. Dis. Sci., 47, 1073–1079.

  • Kohonen-Corish MR, Daniel JJ, te Riele H, Buffinton GD and Dahlstrom JE . (2002). Cancer Res., 62, 2092–2097.

  • Kolligs FT, Bommer G and Goke B . (2002). Digestion, 66, 131–144.

  • Lengauer C, Kinzler KW and Vogelstein B . (1997). Nature, 386, 623–627.

  • Lindblom A . (2001). Curr. Opin. Oncol., 13, 63–69.

  • Liyanage M, Coleman A, du Manoir S, Veldman T, McCormack S, Dickson RB, Barlow C, Wynshaw-Boris A, Janz S, Wienberg J, Ferguson-Smith MA, Schrock E and Ried T . (1996). Nat. Genet., 14, 312–315.

  • Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P and Rognum TO et al. (1993). Cancer Res., 53, 5849–5852.

  • Luceri C, De Filippo C, Caderni G, Gambacciani L, Salvadori M, Giannini A and Dolara P . (2000). Carcinogenesis, 21, 1753–1756.

  • Nambiar PR, Giardina C, Guda K, Aizu W, Raja R and Rosenberg DW . (2002). Cancer Res., 62, 3667–3674.

  • Nambiar PR, Girnun G, Lillo NA, Guda K, Whiteley HE and Rosenberg DW . (2003). Int. J. Oncol., 22, 145–150.

  • Neufeld KL and White RL . (1997). Proc. Natl. Acad. Sci. USA, 94, 3034–3039.

  • Olschwang S, Hamelin R, Laurent-Puig P, Thuille B, De Rycke Y, Li YJ, Muzeau F, Girodet J, Salmon RJ and Thomas G . (1997). Proc. Natl. Acad. Sci. USA, 94, 12122–12127.

  • Rajagopalan H, Nowak MA, Vogelstein B and Lengauer C . (2003). Nat. Rev. Cancer, 3, 695–701.

  • Ried T, Heselmeyer-Haddad K, Blegen H, Schrock E and Auer G . (1999). Genes Chromosomes Cancer, 25, 195–204.

  • Ried T, Knutzen R, Steinbeck R, Blegen H, Schrock E, Heselmeyer K, du Manoir S and Auer G . (1996). Genes Chromosomes Cancer, 15, 234–245.

  • Sheng H, Shao J, Williams CS, Pereira MA, Taketo MM, Oshima M, Reynolds AB, Washington MK, DuBois RN and Beauchamp RD . (1998). Carcinogenesis, 19, 543–549.

  • Sohn KJ, Choi M, Song J, Chan S, Medline A, Gallinger S and Kim YI . (2003). Carcinogenesis, 24, 217–224.

  • Takahashi M, Mutoh M, Kawamori T, Sugimura T and Wakabayashi K . (2000a). Carcinogenesis, 21, 1319–1327.

  • Takahashi M, Nakatsugi S, Sugimura T and Wakabayashi K . (2000b). Carcinogenesis, 21, 1117–1120.

  • Thibodeau SN, Bren G and Schaid D . (1993). Science, 260, 816–819.

  • Tomlinson I, Halford S, Aaltonen L, Hawkins N and Ward R . (2002). J. Pathol., 197, 6–13.

  • Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL . (1988). N. Engl. J. Med., 319, 525–532.

  • Walchle C, Diwan BA, Shiao YH and Calvert RJ . (1999). Toxicol. Appl. Pharmacol., 157, 9–15.

  • Wang QS, Papanikolaou A, Sabourin CL and Rosenberg DW . (1998). Carcinogenesis, 19, 2001–2006.

  • Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, Deng CX and Ried T . (2002). Oncogene, 21, 5097–5107.

  • Whitehall VL, Walsh MD, Young J, Leggett BA and Jass JR . (2001). Cancer Res., 61, 827–830.

  • Wong MH, Hermiston ML, Syder AJ and Gordon JI . (1996). Proc. Natl. Acad. Sci. USA, 93, 9588–9593.

  • Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R, George J, Goldblatt J, Walpole I, Robin SA, Borten MM, Stitz R, Searle J, McKeone D, Fraser L, Purdie DR, Podger K, Price R, Buttenshaw R, Walsh MD, Barker M, Leggett BA and Jass JR . (2001). Am. J. Pathol., 159, 2107–2116.

Download references

Acknowledgements

This work was supported in part by NIH grant CA81428 to DWR.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thomas Ried.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guda, K., Upender, M., Belinsky, G. et al. Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. Oncogene 23, 3813–3821 (2004). https://doi.org/10.1038/sj.onc.1207489

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207489

Keywords

This article is cited by

Search

Quick links